MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. CommentaryLINDHOLM, Lars H.Lancet (British edition). 2003, Vol 361, Num 9374, pp 2000-2001, issn 0140-6736, 14 p.Article

Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policyPERSSON, Mats; CARLBERG, Bo; TAVELIN, Björn et al.Journal of hypertension. 2004, Vol 22, Num 1, pp 65-71, issn 0263-6352, 7 p.Article

Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension TrialBAKRIS, George L; LINDHOLM, Lars H; BLACK, Henry R et al.Hypertension (Dallas, Tex. 1979). 2010, Vol 56, Num 5, pp 824-830, issn 0194-911X, 7 p.Article

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFYHRQUIST, Frej; DAHLÖF, Björn; LINDHOLM, Lars H et al.Hypertension (Dallas, Tex. 1979). 2005, Vol 45, Num 4, pp 580-585, issn 0194-911X, 6 p.Article

High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. CommentaryWEINEHALL, Lars; ÖHGREN, Bengt; PERSSON, Mats et al.Journal of hypertension. 2002, Vol 20, Num 10, pp 1949-1950, issn 0263-6352, 10 p.Article

Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA samplePERSSON, Mats; CARLBERI, Bo; WEINEHALL, Lars et al.Journal of hypertension. 2003, Vol 21, Num 6, pp 1089-1095, issn 0263-6352, 7 p.Article

Does blood pressure differ between users and non-users of hormone replacement therapy? The women's health in the lund area (WHILA) studyENSTRÖM, Inger; LIDFELDT, Jonas; LINDHOLM, Lars H et al.Blood pressure. 2002, Vol 11, Num 4, pp 240-243, issn 0803-7051Article

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension : the RENAAL and LIFE studiesEIJKELKAMP, Wouter B. A; ZHONGXIN ZHANG; PARVING, Hans-Henrik et al.Journal of hypertension. 2007, Vol 25, Num 4, pp 871-876, issn 0263-6352, 6 p.Article

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension studyOKIN, Peter M; DEVEREUX, Richard B; DAHLOF, Björn et al.Circulation (New York, N.Y.). 2006, Vol 113, Num 12, pp 1588-1596, issn 0009-7322, 9 p.Article

The impact of serum uric acid on cardiovascular outcomes in the LIFE studyHØIEGGEN, Aud; ALDERMAN, Michael H; LINDHOLM, Lars H et al.Kidney international. 2004, Vol 65, Num 3, pp 1041-1049, issn 0085-2538, 9 p.Article

Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with hypertension 2: a 5-year, prospective, randomised, controlled trialLINDHOLM, Lars H; ANDERSON, Harald; SCHERSTEN, Bengt et al.Lancet (British edition). 2001, Vol 358, Num 9281, pp 539-544, issn 0140-6736Article

Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settingsMENDIS, Shanthi; LINDHOLM, Lars H; WU FAN et al.Journal of clinical epidemiology. 2011, Vol 64, Num 12, pp 1451-1462, issn 0895-4356, 12 p.Article

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy : the Losartan Intervention For Endpoint reduction in hypertension studyOLSEN, Michael Hecht; WACHTELL, Kristian; LEDERBALLE-PEDERSEN, Ole et al.Journal of hypertension. 2009, Vol 27, Num 3, pp 567-574, issn 0263-6352, 8 p.Article

Cost effectiveness of losartan in patients with hypertension and LVH : an economic evaluation for Sweden of the LIFE trialJÖNSSON, Bengt; CARIDES, George W; BURKE, Thomas A et al.Journal of hypertension. 2005, Vol 23, Num 7, pp 1425-1431, issn 0263-6352, 7 p.Article

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. CommentaryJULIUS, Stevo; KJELDSEN, Sverre E; PLAT, Francis et al.Lancet (British edition). 2004, Vol 363, Num 9426, pp 2010-2011, issn 0140-6736, 12 p.Article

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE StudyWACHTELL, Kristian; IBSEN, Hans; FYHRQUIST, Frej et al.Annals of internal medicine. 2003, Vol 139, Num 11, pp 901-906, issn 0003-4819, 6 p.Article

Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension studyCICALA, Silvana; DE SIMONE, Giovanni; GERDTS, Eva et al.Journal of hypertension. 2010, Vol 28, Num 6, pp 1134-1140, issn 0263-6352, 7 p.Article

Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy : The Losartan Intervention For End point reduction in hypertension (LIFE) studyOLSEN, Michael Hecht; WACHTELL, Kristian; LINDHOLM, Lars H et al.The American heart journal. 2009, Vol 157, Num 1, pp 177-184, issn 0002-8703, 8 p.Article

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death the life studyWACHTELL, Kristian; OKIN, Peter M; OLSEN, Michael H et al.Circulation (New York, N.Y.). 2007, Vol 116, Num 7, pp 700-705, issn 0009-7322, 6 p.Article

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. CommentaryIBSEN, Hans; WACHTELL, Kristian; JULIUS, Stevo et al.Journal of hypertension. 2004, Vol 22, Num 9, pp 1679-1681, issn 0263-6352, 10 p.Article

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE Study. CommentaryLINDHOLM, Lars H; DAHLÖF, Björn; EDELMAN, Jonathan M et al.Lancet (British edition). 2003, Vol 362, Num 9384, pp 591-592, issn 0140-6736, 4 p.Article

Cardiovascular morbidity and mortality in the Losartan intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololDAHLÖF, Björn; DEVEREUX, Richard B; LINDHOLM, Lars H et al.Lancet (British edition). 2002, Vol 359, Num 9311, pp 995-1003, issn 0140-6736Article

Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) studyKJELDSEN, Sverre E; HEDNER, Thomas; SYVERTSEN, Jan Otto et al.Journal of hypertension. 2002, Vol 20, Num 6, pp 1231-1237, issn 0263-6352Article

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLINDHOLM, Lars H; IBSEN, Hans; JULIUS, Stevo et al.Journal of hypertension. 2002, Vol 20, Num 9, pp 1879-1886, issn 0263-6352Article

Greater Regression of Electrocardiographic Left Ventricular Hypertrophy During Hydrochlorothiazide Therapy in Hypertensive PatientsOKIN, Peter M; HILLE, Darcy A; KJELDSEN, Sverre E et al.American journal of hypertension. 2010, Vol 23, Num 7, pp 786-793, issn 0895-7061, 8 p.Article